✨ Free AI Report
Annexon Inc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Annexon Inc
Company Research

Annexon Inc: Business Overview, Financials & Competitive Analysis

Annexon Inc scores 5/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage C1q inhibitor platform with differentiated mechanism targeting validated inflammatory pathways, but requires successful Phase 3 outcomes for valuation inflection. Annexon is advancing multiple late-stage assets in well-validated pathways addressing large orphan and broad markets (GBS, geographic atrophy, neurodegenerative diseases). However, as a clinical-stage biotech, it faces execution risk and.

What is Annexon Inc's industry? Annexon Inc (annexonbio.com) operates in Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases. AskCyborg classifies Annexon Inc under Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases in its company registry.

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body,...

5/ 10Solid

Cyborg Score thesis

Clinical-stage C1q inhibitor platform with differentiated mechanism targeting validated inflammatory pathways, but requires...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Annexon Inc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Annexon Inc

AskCyborg analysts argue the bull and bear cases for Annexon Inc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Annexon Inc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Annexon Inc Overview

Pro stress-test →

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company is focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases.

Strategic Profile

Pro stress-test →

Annexon's platform technology addresses classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, advancing a portfolio of product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). ANX005 is in Phase 3 clinical trial for guillain-barré syndrome and Phase 2a for amyotrophic lateral sclerosis, while ANX007 is in Phase 3 for geographic atrophy treatment.

Competitive Landscape

Pro stress-test →

Competitors in the complement/neurodegenerative space include Alector, Sorrento Therapeutics, Vedanta Biosciences, Alzheon, and CRISPR Therapeutics. Annexon's C1q-focused mechanism provides differentiation versus broader complement inhibitors. As a clinical-stage player, it competes against both established pharma programs and other biotech developers targeting similar disease areas.

Industry Context

Annexon Inc operates in Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases.

Key facts

Founded: 2011 · Headquarters: Brisbane, California, US · Employees: 117 · Market cap: $759M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Annexon Inc.

  • Leading product ANX005 (tanruprubart) progressing in Phase 3 for Guillain-Barré Syndrome with focused GBS awareness campaign launched in early 2025
  • Three-pronged platform approach addresses multiple routes of administration and disease targets—systemic, intravitreal, and subcutaneous—enabling broad market penetration
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Presenting at TD Cowen 46th Annual Health Care Conference with KOL event on vonaprument for geographic atrophy
  • May 2025Reported improved outcomes with tanruprubart at Peripheral Nerve Society Annual Meeting; launching disease awareness campaign for GBS
  • +1 moreTrack every material event for Annexon Inc as it happens. Explore monitoring →
Get alerted when Annexon Inc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AlectorNeuroinflammation and neurodegeneration therapies→Sorrento TherapeuticsImmunotherapy and oncology focused platform→Vedanta BiosciencesImmunology and microbiome therapeutics→

Compare Annexon Inc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Annexon Inc operates in Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases research →
NEW · MCP server

Ask your AI assistant about Annexon Inc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Annexon Inc and its top competitor on Cyborg Score”
“What did Annexon Inc do this quarter?”
“Is Annexon Inc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Annexon Inc do?+
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body,...
What is Annexon Inc's Cyborg Score?+
Annexon Inc has a Cyborg Score of 5/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Annexon Inc's main competitors?+
Named competitors include Alector, Sorrento Therapeutics, Vedanta Biosciences. The full competitive landscape is in the AskCyborg report.
How can I get the full Annexon Inc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Annexon Inc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Annexon Inc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Neurodegenerative & Autoimmune Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Alector, Inc.